Cost-Effectiveness of Adjuvant Immunotherapy With Cytokine-Induced Killer Cell for Hepatocellular Carcinoma Based on a Randomized Controlled Trial and Real-World Data

BACKGROUND: Studies using data from randomized controlled trials (RCTs) and real-world data (RWD) have suggested that adjuvant cytokine-induced killer (CIK) cell immunotherapy after curative treatment for hepatocellular carcinoma (HCC) prolongs recurrence-free survival (RFS) and overall survival (OS...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Jeong-Yeon, Kwon, Sun-Hong, Lee, Eui-Kyung, Lee, Jeong-Hoon, Kim, Hye-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8682810/
https://www.ncbi.nlm.nih.gov/pubmed/34926248
http://dx.doi.org/10.3389/fonc.2021.728740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8682810/
https://www.ncbi.nlm.nih.gov/pubmed/34926248
http://dx.doi.org/10.3389/fonc.2021.728740

Ejemplares similares